Welcome to our dedicated page for PERK LABS news (Ticker: $PKLBF), a resource for investors and traders seeking the latest updates and insights on PERK LABS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PERK LABS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PERK LABS's position in the market.
Perk Labs Inc. provided an update on the status of a management cease trade order (MCTO) application to the British Columbia Securities Commission. The Company was granted a voluntary MCTO to file its audited annual financial statements and related management's discussion and analysis. The MCTO prohibits trading by the CEO and CFO but not other shareholders. The Company aims to complete the filings by May 31, 2024, and will issue bi-weekly default status reports until then.
Perk Labs Inc. announces an agreement with Gibson & Associates for a custom payment portal. Gibson & Associates has chosen Perk's subsidiary, Getit Technologies Inc., as its payment technology provider. The custom-branded payment portal offers convenient online payments through a button embedded in Gibson & Associates' website. Getit's technology allows for quick credit card processing and recurring billing options, catering to the needs of Gibson & Associates' clients.
